Walleye Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Walleye Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,000	Closed	-$1.22M	–	4971
2025 Q1	$1.22M	Buy	+23,000	New	+$1.28M	0.01%	1808

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Capital's RYTM Position: Q4 2025 in Review

Walleye Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 50,181 shares — an estimated $5.07M sold.

Walleye Capital first reported a position in RYTM in Q3 2021 and held it in 7 quarters. The position peaked at $8.08M in Q4 2024. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

Walleye Capital reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 50,181 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $5.07M.
Walleye Capital first reported a position in Rhythm Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Walleye Capital's Rhythm Pharmaceuticals position peaked at $8.08M in Q4 2024.
279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.